Phathom Pharmaceuticals, Inc. (PHAT) 2025 Q4 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Hello and welcome to Fathom Pharmaceuticals 4th quarter and full year 2025 earnings results call. (Operator Instruction) I would like to turn the call over to Eric Sciarrelli, Fathom's head of investor relations. Please go ahead.

    大家好,歡迎參加Fathom Pharmaceuticals 2025年第四季及全年財報電話會議。 (操作說明)現在我將把電話會議交給Fathom投資者關係主管Eric Sc​​harrelli先生。請開始。

  • Eric Sciorilli - Head of investor relations

    Eric Sciorilli - Head of investor relations

  • Thank you operator. Hello everyone and thank you for joining us this morning to discuss z's fourth quarter and full year 2025 results. This morning's presentation will include remarks from Steve Basta, our President and CEO, and Sanjeev Nulla, our Chief Financial and Business Officer. A couple of notes before we get started. Earlier this morning, we issued a press release detailing the results we will be discussing during the call. A copy of that press release can be found under the news releases section of our corporate website. Further, the recording of today's webcast and the slides we will be reviewing can also be found on our corporate website under the events and presentations section.

    謝謝接線生。大家好,感謝各位今天上午參加我們的電話會議,共同探討公司2025年第四季及全年業績。今天早上的會議將由我們的總裁兼執行長Steve Basta和財務長兼首席商務官Sanjeev Nulla致辭。在正式開始之前,有幾點需要說明。今天早上早些時候,我們發布了一份新聞稿,詳細介紹了我們將在電話會議中討論的表現。您可以在我們公司網站的「新聞稿」欄位中找到該新聞稿的副本。此外,今天網路直播的錄影以及我們將要討論的幻燈片也可以在我們公司網站的「活動與簡報」欄位中找到。

  • Before we begin, let me remind you that we will be making a number of forward-looking statements throughout today's presentation. These forward-looking statements involve risks and uncertainties, many of which are beyond Fathom's control. Actual results may materially differ from the forward-looking statements, and any such risks may materially adversely affect our business and results of operations and the trading prices for Fathom's common stock. A discussion of these statements and risk factors is available in the current Safe Harbor slide, as well as in the risk factors section of our most recent Form 10k and subsequent SEC filings.

    在正式開始之前,請允許我提醒各位,在今天的演示過程中,我們將做出一些前瞻性陳述。這些前瞻性陳述涉及風險和不確定性,其中許多風險和不確定性超出了Fathom的控制範圍。實際結果可能與前瞻性陳述有重大差異,任何此類風險都可能對我們的業務和經營業績以及Fathom普通股的交易價格產生重大不利影響。關於這些陳述和風險因素的討論,請參閱目前的「安全港聲明」投影片,以及我們最新的10-K表格和後續提交給美國證券交易委員會(SEC)文件中「風險因素」部分的內容。

  • All forward-looking statements made on this call are based on the beliefs of Fathom as of this date, and Fathom disclaims any obligation to update these statements. Later in the call, we will be commenting on both GAAP and non-GAAP financial measures. Specifically in the scope of this discussion, when we refer to cash operating expenses, please note we are referring to the non-GAAP form of this measure, which excludes non-cash stock-based compensation. As always, detailed reconciliations between our non-GAAP results and the most directly comparable GAAP measures are included in this morning's press release. With that, I will now turn the call over to Steve Basta, Batham's President and CEO, to kick us off. Steve.

    本次電話會議中所有前瞻性陳述均基於Fathom截至發布之日的信念,Fathom不承擔更新這些陳述的任何義務。稍後,我們將對GAAP和非GAAP財務指標進行評述。特別地,在本次討論中,當我們提及現金營運支出時,請注意我們指的是該指標的非GAAP形式,其中不包括非現金的股權激勵支出。與往常一樣,我們今天早上的新聞稿中包含了非GAAP績效與最直接可比較的GAAP指標之間的詳細調整表。接下來,我會把電話會議交給Fathom總裁兼執行長Steve Basta先生,由他來開始今天的討論。 Steve。

  • Steven Basta - President and CEO

    Steven Basta - President and CEO

  • Thank you, Eric, and thank you to our investors and analysts for joining our call this morning. Thank you even more to the Fathom colleagues for your diligence and dedication throughout 2025. It was a transformational year for the company, and we're now set to execute our growth and profitability plan. Let me start by summarizing the key points Sanjeev and I will be discussing today. We had a successful Q4. We delivered on expectations for both revenue and cash operating expense levels coming in at the better end of our guided ranges.

    謝謝艾瑞克,也感謝各位投資人和分析師今天上午參加我們的電話會議。更要感謝Fathom的各位同事,感謝你們在2025年付出的辛勤努力和奉獻。對公司而言,這是具有變革意義的一年,我們現在已做好準備,執行成長和獲利計畫。首先,讓我總結一下我和桑吉夫今天將要討論的要點。我們第四季業績斐然。收入和現金營運支出水平均達到預期,且均處於我們預期範圍的較高水準。

  • We've taken key steps in the recent two months to enhance our capital structure, reduce our interest expense, and modify our outstanding term loan obligations. As a result, we believe our cash on hand, along with anticipated future cash generated from operations will be sufficient to satisfy all obligations under both our term debt and our revenue interest financing agreements. We're on track in guiding to operating profitability beginning in Q3 of this year and for full year 2026. Our $320 million to $345 million revenue guidance. For 2026 reflects our operating expectation of continued solid growth from our GI focused strategy and includes an accounting-related classification change which Sanji will cover in more detail.

    近兩個月,我們採取了關鍵措施來優化資本結構、降低利息支出並調整未償還的定期貸款。因此,我們相信,現有現金以及預期未來營運產生的現金足以償還所有定期債務和收益利息融資協議項下的債務。我們預計今年第三季開始實現營運盈利,並預計在2026年全年實現盈利。我們預計2026年營收為3.2億美元至3.45億美元,這反映了我們對以一般投資為重點的策略將持續穩健增長的營運預期,並包含一項會計分類變更,Sanji將在後續文章中對此進行更詳細的闡述。

  • Our sales organization is positioned to deliver, and we're seeing clear signs that our GI strategy is working. I'm very proud of what our team accomplished in 2025. We believe we've set ourselves up for success both financially and operationally. Beginning the update today with our financial highlights for Q4 and full year 2025, our results are in line with our pre-announced estimates from January and incrementally a bit better on expenses and on cash usage.

    我們的銷售團隊已做好充分準備,能夠交付成果,我們看到了全球保險策略正在發揮作用的明顯跡象。我為我們團隊在2025年所取得的成就感到非常自豪。我們相信,無論在財務或營運方面,我們都已為成功做好了充分準備。今天,我們首先發布2025年第四季和全年的財務亮點,我們的業績與1月份公佈的預期基本一致,並且在支出和現金使用方面略有改善。

  • We've delivered on the plan we set forth on our May earnings call and reiterated our earnings calls in August and in October. Net revenues were $175.1 million for the full year 2025, representing 217% year over year growth. Q4 sequential quarterly growth was solid during a period of salesforce alignment as we had discussed in our October call. In August we guided to $165 million to $175 million for 2025 revenue. We updated that in October to 170 to $175 million, narrowing it to the top half of the range, and ultimately, we delivered at the high end of that range. Our Q4 revenue was $57.6 million in line with our pre-release January estimate of $57 to $58 million.

    我們實現了5月財報電話會議上所製定的計劃,並在8月和10月的財報電話會議上重申了這項計劃。 2025年全年淨收入為1.751億美元,年增217%。正如我們在10月份的電話會議上所討論的,在銷售團隊調整期間,第四季環比成長依然穩健。 8月份,我們預計2025年營收為1.65億美元至1.75億美元。 10月份,我們將這一預期上調至1.7億美元至1.75億美元,範圍縮小至區間的上半部分,最終,我們實現了該區間的上限。第四季營收為5,760萬美元,與我們1月發布財報前的預估5,700萬美元至5,800萬美元基本一致。

  • Cash operating expenses, excluding stock-based compensation were $50.3 million for Q4, better than both the less than $55 million target we guided to and to our pre-announced range of $51 to $53 million. We delivered solid growth through the last three quarters of 2025 while cutting quarterly cash operating expenses by nearly 50%. Our net cash usage for Q4 of 2025 was approximately $5 million. That's 64% lower than Q3 and consistent with our expectations of reaching operating profitability beginning in Q3 2026 and cash flow positivity in 2027. We've taken significant steps to enhance our capital structure.

    第四季現金營運支出(不計股權激勵費用)為5,030萬美元,優於我們先前預期的低於5,500萬美元的目標,也優於我們預先公佈的5,100萬至5,300萬美元的區間。在2025年最後三個季度,我們實現了穩健成長,同時將季度現金營運支出削減了近50%。 2025年第四季淨現金使用量約為500萬美元,較第三季下降64%,符合我們預期,即從2026年第三季開始實現營運獲利,並在2027年實現現金流為正。我們已採取重要措施優化資本結構。

  • Our goals were one to reduce any financing overhang or potential risks stemming from repayment obligations or cash covenants. And 2, to reduce our interest expenses. In 2025, we got the fundamentals of our business in order, growing revenue and reducing expenses. That improved financial profile enabled us to complete a successful equity offering in January and renegotiate our debt terms as we announced today.

    我們的目標有兩個:一是減少任何融資負擔或因償還義務或現金契約而產生的潛在風險;二是降低利息支出。到了2025年,我們理順業務的基本面,實現了收入成長和支出下降。財務狀況的改善使我們能夠在1月成功完成股權發行,並如今天宣布的那樣,重新談判了債務條款。

  • We have modified our term loan agreement. To extend the maturity date, which had previously been December of 2027, we've extended it to February 2029. And we've reduced our interest expense obligation and reduced the total outstanding principal amount. As a result of these capital structure enhancements, we believe our current cash plus the cash that we're expected to generate from operations in the coming years will be sufficient to meet all obligations under both our term loan and our revenue interest financing agreements.

    我們已修改了定期貸款協議。原定到期日為2027年12月,現已延至2029年2月。同時,我們降低了利息支出,並減少了未償還本金總額。由於這些資本結構優化措施,我們相信,目前的現金加上未來幾年預計從營運活動中產生的現金,足以履行定期貸款協議和收益利息融資協議項下的所有義務。

  • Sanj will provide further details on these items and take you through our 2026 guidance. I'm very proud of our operating and financial progress these last 12 months. The entire Fathom team is dedicated to our objectives of growing revenue while being disciplined on expenses. We're exhibiting strong momentum which we expect to carry forward throughout 2026. A few quick notes on our commercial progress. I said before how fortunate we are to be able to possibly impact the lives of so many patients.

    Sanj 將就這些事項提供更多詳情,並向您介紹我們 2026 年的業績指引。我對過去 12 個月我們在營運和財務方面取得的進展感到非常自豪。 Fathom 的全體團隊都致力於實現我們的目標:在嚴格控制支出的同時,實現收入成長。我們目前發展勢頭強勁,預計這一勢頭將持續到 2026 年。關於我們的商業進展,還有幾點需要簡單說明。我之前說過,我們非常榮幸能夠有機會影響這麼多患者的生活。

  • Through February 13th, over 1.1 million Fuesna total prescriptions have been filled to more than 230,000 patients. We believe we're just starting to penetrate an enormous market. About 65 million patients have gastroesophageal reflux. Of which 40% experience inadequate symptom relief from PPIs. About 273,000 prescriptions were filled in Q4 alone. 174,000 of these were covered prescriptions, growing 21% quarter over quarter and representing approximately 64% of the total prescriptions filled in Q4, while 99,000 were filled as cash paid prescriptions.

    截至2月13日,Fuesna已累計開立超過110萬張處方,惠及超過23萬名患者。我們相信,我們才剛開始開拓這個龐大的市場。全球約有6500萬胃食道逆流患者,其中40%的患者服用質子幫浦抑制劑(PPI)後症狀緩解不足。光是第四季就開立了約27.3萬張處方。其中17.4萬張為健保覆蓋處方,季增21%,約佔第四季處方總量的64%;另有9.9萬張為自費處方。

  • Covered prescription volume drives our revenues while cash paid prescription volume improves physician perception of access and makes it easier for physicians to prescribe Oresna with confidence that their patients will be able to get the drug. Most importantly, both paths enable us to help patients in need of Oquesna. Additionally, in November, we turned on a GoodRx offering, providing an alternative payment option for patients filling the prescriptions sent to retail pharmacies.

    健保覆蓋的處方量是我們收入的主要來源,而現金支付的處方量則能提升醫生對藥物可及性的認知,使他們更有信心為患者開具奧瑞斯納(Oresna)處方,確保患者能夠獲得該藥物。最重要的是,這兩種途徑都能幫助我們幫助到需要奧瑞斯納的病人。此外,我們在11月推出了GoodRx服務,為前往零售藥房取藥的患者提供了一種新的支付選擇。

  • Looking forward, we have confidence in 2026 growth. We just completed our national sales meeting and the sentiment from the field is terrific. We start March with more than 285 of our 300 sales positions currently filled, a nearly full strength sales organization. Our strategy to drive depth and frequency of calls to gastroenterologists is solid, and we believe it will ramp utilization and writing frequency among GIs treating GERD.

    展望未來,我們對2026年的成長充滿信心。我們剛結束了全國銷售會議,來自銷售部門的回饋非常正面。三月初,我們300個銷售職位中已有超過285個有人任職,銷售團隊幾乎滿員。我們旨在提高與胃腸病學家溝通的深度和頻率的策略行之有效,我們相信這將提高胃腸病學家對治療胃食道逆流(GERD)的利用率和處方頻率。

  • 2026 will be an important year for us as we drive sales growth and transition to profitability. Overall, we continue to deliver as we guided on each of our previous earnings calls. Our 2025 results ended at the better ends of our revenue and cash operating expense guidance ranges we communicated, and we believe we're on track to transition to operating profitability beginning in Q3 of this year and to reach cash flow positivity in 2027.

    2026年對我們而言將是至關重要的一年,我們將致力於推動銷售成長並實現獲利轉型。整體而言,我們持續兌現先前每次財報電話會議的預期。 2025年的業績最終達到我們先前公佈的收入和現金營運支出預期範圍的上限,我們相信,我們正按計劃推進,將於今年第三季度開始實現營運盈利,並在2027年實現現金流為正。

  • We've taken important steps to enhance our capital structure and mitigate any covenant or repayment concerns. The sales force is full strength and energized following a national sales meeting. We're well positioned to execute and deliver on our strategy in 2026. I'll now turn the call over to Sanjeev to take you through our detailed financial updates.

    我們已採取重要措施優化資本結構,並降低任何契約或還款的擔憂。全國銷售會議結束後,銷售團隊士氣高昂,人員充足。我們已做好充分準備,在2026年執行並實現我們的戰略目標。現在,我將把電話交給桑吉夫,讓他為大家詳細介紹我們的財務更新。

  • Sanjeev Narula - Chief Financial and Business Officer

    Sanjeev Narula - Chief Financial and Business Officer

  • Thank you, Stephen. Hello, everyone. I'm pleased to report our Q4 and full year 2025 results today. I'm encouraged by the changes we've made throughout 2025 and excited about what's on the horizon for 2006 and beyond. We have a lot of important updates on the financial front, so let me get right into it. Steve provided some top-level highlights for the quarter, and I'll provide additional color commentary.

    謝謝史蒂芬。大家好。我很高興今天向大家報告我們2025年第四季及全年業績。我對2025年所做的調整感到鼓舞,也對2026年及以後的發展前景充滿期待。我們在財務方面有很多重要的更新,那麼我就直接進入正題了。史蒂夫已經介紹了本季度的一些主要亮點,我將補充一些細節分析。

  • Revenues for Q4 of $57.6 million were consistent with pre-release and demonstrated 16% sequential quarterly growth. Aligned with the full year, the core also came in at the very top end of our guidance. As always, covered script volume primarily drive our revenue, while contribution from cash scripts and inventory dynamics remain minimal and consistent.

    第四季營收為5,760萬美元,與預測相符,季增16%。與全年預期一致,核心營收也達到了我們預期的上限。一如既往,健保處方量是我們營收的主要動力,而現金處方和庫存動態的貢獻仍然微乎其微且穩定。

  • Our gross net for Q4 came in at the higher end of 55% to 60% range we provided last quarter as a result of shifting rebating mix. Our full year gross net was within our expectations. Our gross margin remained consistent in Q4 and full year. At approximately 87%. After accounting for quarterly cash expenses, we reported a loss from operations excluding stock-based compensation of approximately 3,200, a 95% improvement compared to Q3. As you can see, this is a meaningful change in the operating profile of our company.

    由於返利組合的變化,我們第四季的毛淨率達到了上季預期的55%至60%區間的較高水準。全年毛淨率符合預期。第四季和全年的毛利率保持穩定,約87%。在扣除季度現金支出後,我們報告的營業虧損(不包括股權激勵支出)約為3,200美元,較第三季改善了95%。如您所見,這標誌著我們公司經營狀況的顯著改善。

  • As always, please refer to this morning's press release for reconciliation between non-GAAP measures and their most directly comparable GAAP measures. Q4 cash operating expenses were about 50 million, notably favorable than the less than 55 million guidance we set forth earlier last year due to continued expense discipline. Similarly, our full year cash operating expenses of approximately 284 million came in at the low end of the range we provided on our Q3 call. We ended the year with about $130 million in cash and cash equivalent, which roughly reflects a 5 million cash usage in Q4 and signals a very clear path to operating profitability this year.

    與往常一樣,請參閱今天上午的新聞稿,以了解非GAAP指標與其最直接可比較的GAAP指標之間的調節表。第四季現金營運支出約為5000萬美元,由於我們持續嚴格控制支出,這一數字顯著優於去年年初我們給出的不到5500萬美元的預期。同樣,我們全年現金營運支出約為2.84億美元,處於我們在第三季電話會議上給出的預期範圍的下限。年底,我們持有約1.3億美元的現金及現金等價物,這大致反映了第四季度約500萬美元的現金支出,並預示著今年實現營運盈利的清晰路徑。

  • Now let me turn to the enhancement in our capital structure. In January we improved our capital structure while oversubscribed equity offering and today we're announcing a modification of our term debt. As a result of these deliberate steps, we believe we now have a cost effective and sustainable capital structure to meet our business needs and all of our debt obligations. The offering raised $130 million in gross proceeds which brought our cash balance just north of 250 million at the start of the year.

    現在,我想談談我們資本結構的最佳化。今年1月,我們在超額認購的股權發行中優化了資本結構,今天我們宣布對定期債務進行調整。透過這些審慎的舉措,我們相信目前已擁有成本效益高且可持續的資本結構,能夠滿足業務需求並履行所有債務義務。此次發行共籌集資金1.3億美元,使我們年初的現金餘額略高於2.5億美元。

  • I'm pleased to announce today that we have successfully modified the terms of our outstanding term facility which we believe would greatly benefit the company going forward. We reduced the remaining principal to $175 million outstanding and paid certain end of term fees and accrued paid in current amounts from the original agreement. In total we used approximately 56 million of our cash balance to streamline this facility.

    我很高興地宣布,我們已成功修改了現有定期貸款的條款,我們相信這將極大地有利於公司未來的發展。我們將剩餘本金減少至1.75億美元,並支付了部分期末費用以及根據原協議按當前金額計提的應計款項。我們總共動用了約5,600萬美元的現金餘額來簡化這項貸款。

  • Additionally, we were successful in lowering the interest rate from 12% to 9.85%. Lastly, we extended the loan maturity date from December 2027 to February 2029. Partial monthly repayments will begin in 2028, which are anticipated to reduce the outstanding principal as well as our interest expenses. We expect we will be generating positive operating cash flow beginning in 2027 in advance of the repayment obligations.

    此外,我們成功將利率從12%降至9.85%。最後,我們將貸款到期日從2027年12月延至2029年2月。部分月供將於2028年開始,預計將減少未償還本金和利息支出。我們預計,在償還貸款之前,我們將從2027年開始產生正的經營現金流。

  • Overall, these modified terms reduce our interest expense, remove near term payment hurdles, and provide greater financial flexibility. Following our capital structure enhancement, we believe our cash on hand, along with anticipated future cash flow from operations, will be sufficient to invest in our operations as needed and to satisfy all liquidity governance and repayment obligations.

    總體而言,這些修改後的條款降低了我們的利息支出,消除了近期付款障礙,並提供了更大的財務靈活性。在優化資本結構後,我們相信,我們現有的現金以及預期的未來營運現金流量足以滿足我們營運所需的投資,並履行所有流動性管理和償還義務。

  • For complete clarity on our covenant, we expect our highest casual requirement between now and September 30th, 2027 will be approximately 130 million. The cash flow requirement is derived from our covenant on in our revenue interest financing agreement which becomes effective for the first time on October 1st, 2026.

    為了更清楚地闡明我們的契約,我們預計從現在到2027年9月30日,我們最高的臨時現金需求約為1.3億美元。此現金流需求源自於我們收益權益融資協議中的契約,該協議將於2026年10月1日首次生效。

  • All casual requirements relating to a term that are substantially lower than those from our revenue interest financing agreement. Beginning October 1st, 2027, we expect revenue interest financing agreement covenants will require that we temporarily hold a modestly high cash balance, which will decline thereafter as revenues increase and we make additional royalty payments. To be clear, the casual covenants between the term debt and revenue interest financing agreements are not addicted.

    所有與定期債務相關的臨時性要求均遠低於我們收益權益融資協議中的要求。自2027年10月1日起,我們預期收益權益融資協議的契約將要求我們暫時維持較高的現金餘額,此後隨著收入成長和我們支付額外特許權使用費,現金餘額將逐漸下降。需要明確的是,定期債務協議和收益權益融資協議之間的臨時性契約並非相互關聯。

  • We manage our liquidity to whichever covenant is the highest at any given point in time. Rest assured for all these periods we believe our cash on hand of approximately $190 million following our term debt modification and our anticipated cash generated from operations beginning in 2027 will be sufficient to satisfy all covenants at all times.

    我們會根據具體時間點的最高契約條款來管理流動性。請放心,我們相信,在完成定期債務重組後,我們約1.9億美元的現金儲備以及預計從2027年開始的經營活動產生的現金流,足以滿足所有契約條款的要求。

  • We refer you to our 10k file earlier this morning for more information. While on the topic of our 10k, I'd like to flag that in this year's document we updated the business section and risk factors to reflect the company's transition to a primarily commercial entity. While a comparison against prior years will show significant tax changes, I want to be clear that we believe important updates have been covered during this earnings call and in this morning's press release. Now I'd like to move to our 2026 guidance with our GI focused strategy taking hold and our financial position enhanced, we're ready to deliver in 2026.

    更多資訊請參閱我們今天早上發布的10-K文件。關於10-K文件,我想特別指出,今年的文件中,我們更新了業務部分和風險因素,以反映公司向以商業為主的實體轉型。雖然與往年相比,稅務方面會有顯著變化,但我想強調的是,我們認為本次財報電話會議和今天早上的新聞稿已經涵蓋了重要的更新內容。現在,我想談談我們對2026年的業績展望。隨著我們以一般投資為重點的策略逐步落實,財務狀況也得到改善,我們已做好準備,在2026年實現預期目標。

  • Today we're issuing guidance on several financial metrics which reflect that sentiment. Before I get into the numbers, I'd like to provide clarity on the accounting related explanatory note you saw in this morning's press release.

    今天,我們將發布幾個反映這種情緒的財務指標指引。在詳細介紹這些數字之前,我想先解釋一下您今天早上在新聞稿中看到的會計相關說明。

  • Beginning January 1st, certain third-party charges will be included in costs of goods sold instead of gross net adjustments. All things equal net revenue will be higher as a result of costs moving from gross net adjustments to cost of goods sold, leading to a mostly net neutral effect on our gross profit line in our P&L.

    自1月1日起,部分第三方費用將計入銷售成本,而非先前的毛利淨額調整。在其他條件不變的情況下,由於這些費用從毛利淨額調整轉入銷售成本,淨收入將會增加,因此對損益表中的毛利影響基本上為中性。

  • Importantly, this change is simply a different classification of these costs and does not impact the underlying operations of our business. We are estimating an approximately 17 to 20 million shifts in 2026 between two-line items, which is reflected in the following guidance. We anticipate 2026 net revenue will be 320 to 345 million including the estimated effect of the classification change I just described.

    重要的是,此次變更僅僅是對這些成本進行了不同的分類,並不影響我們業務的根本運作。我們預計2026年兩項成本項目之間將發生約1700萬至2000萬美元的變動,這已反映在以下業績指引中。我們預計2026年淨收入將達到3.2億至3.45億美元,其中包括我剛才描述的分類變更的預期影響。

  • As for go to net, we believe the discount will be between 55 to 59%. We anticipate gross margin will be approximately 80%. As for spend, we're anticipating cash operating expenses excluding stock-based compensation of 235 to 255 million, which at midpoint reflects a 14% decrease compared to 2025 results. Now a few comments about the cadence of these items over the course of 2026. We believe revenue will exhibit a similar pattern to last year with approximately 40% being achieved in the first half and approximately 60% being achieved in the second half with quarter one being the soft quarter due to typical seasonality.

    至於淨利潤率,我們認為折扣將在 55% 至 59% 之間。我們預計毛利率約為 80%。關於支出,我們預計不包括股權激勵費用的現金營運支出為 2.35 億至 2.55 億美元,取中間值後較 2025 年的業績下降 14%。接下來,我們將對 2026 年各項指標的進展做一些說明。我們認為營收將與去年類似,上半年約佔全年的 40%,下半年約佔 60%,第一季由於季節性因素,業績可能較為疲軟。

  • We expect expenses will be relatively stable on a quarterly basis but will reflect a modest step up from where we exited Q4 2025, accounting for nearly full strength sales team, new marketing initiative, and full year cost of our EOE phase two trial. Based on anticipated revenue, gross profit, and cash operating expenses. We anticipate achieving operational profitability, excluding stock-based compensation by Q3. And in total for full year 2026. And finally, we believe we will achieve cash flow positivity in 2027.

    我們預計季度支出將保持相對穩定,但較2025年第四季末略有增長,這主要得益於銷售團隊接近滿員、新的行銷計劃以及EOE二期臨床試驗的全年成本。基於預期收入、毛利和現金營運支出,我們預計在第三季實現營運獲利(不計股權激勵支出),並預計2026年全年獲利。最後,我們相信將在2027年實現現金流為正。

  • In summary, our financial profile has transitioned meaningfully and I'm excited for this next phase. This quarter results were strong, coming in at the better end of our guidance we previously provided. Our operational momentum is solid, which gives me confidence in our 2026 revenue trajectory. I feel confident in our financial position and believe we have the resources we need to execute the plan and deliver on the guidance ranges we set forth today. With that, I'll now turn the call back to Steve for his closing remarks. Steve.

    總而言之,我們的財務狀況已發生顯著轉變,我對下一階段充滿期待。本季業績表現強勁,超出我們先前給出的預期。我們的營運勢頭穩健,這讓我對2026年的營收成長充滿信心。我對我們的財務狀況充滿信心,並相信我們擁有執行計劃所需的資源,能夠實現今天公佈的業績預期。接下來,我將把電話轉回給史蒂夫,請他做總結發言。史蒂夫。

  • Steven Basta - President and CEO

    Steven Basta - President and CEO

  • Thank you, Sanjeev, for the detailed financial review. I would like to extend my thanks to everyone at Fathom for their extraordinary efforts throughout 2025. I was able to meet many of our sales team members during our recent national sales meeting, and I'm heartened by their dedication and exceptional talent.

    感謝Sanjeev提供的詳盡財務分析。我也要感謝Fathom全體員工在2025年付出的卓越努力。在最近的全國銷售會議上,我有幸與許多銷售團隊成員見面,他們的敬業精神和傑出才能令我深受鼓舞。

  • Our transition to focus on gastroenterologists and to reach operating profitability is well underway. Thank you also to our shareholders for your support and confidence. We're dedicated to delivering value to reward your investment. Operator, please open the line for questions.

    我們向專注於腸胃科醫生和實現盈利的轉型工作進展順利。感謝各位股東的支持與信任。我們將致力於創造價值,回報您的投資。接線員,請接聽提問。

  • Operator

    Operator

  • Yes, sir. Ladies and gentlemen, if you have a question or comment at this time, (Operator Instructions) Our first question or comment comes from the line of Kristen Cluster from Canton Fitzgerald. Ms. Cluster, your line is now open.

    是的,先生。女士們先生們,如果您現在有任何問題或意見,(操作員指示)我們第一個問題或意見來自坎頓·菲茨杰拉德的克里斯汀·克拉斯特女士。克拉斯特女士,您的線路現在可以接通了。

  • Kristen Cluster - Analyst

    Kristen Cluster - Analyst

  • Hi everyone, congrats on a really strong end of the year and the work you were able to do around the interest definitely very favorable here. So, the question I have for you this morning is just recognizing it's still very much early days, what can you tell us about the early signals that you're seeing? Seeing from this strengthened sales force and strategy, especially coming out of that meeting, are you seeing that more the GIs that were new to your strategy are converting and are you also seeing some early signals of growth within those current GIs where you added more touch points? Thank you.

    大家好,恭喜你們年末業績斐然,你們在市場興趣方面所做的工作也確實非常出色。今天早上我想問大家的問題是,雖然現在還處於初期階段,但你們能否分享一下目前觀察到的早期跡象?鑑於你們加強了銷售團隊和策略,尤其是在上次會議之後,你們是否發現,那些之前未納入你們策略的全球經銷商(GI)的轉換率有所提高?同時,在那些你們增加了接觸點的現有全球經銷商中,你們是否也觀察到了一些成長的早期跡象?謝謝。

  • Steven Basta - President and CEO

    Steven Basta - President and CEO

  • Tristan, thanks so much for the kind thoughts and for bringing us to what I think is the most important topic actually, which is the core focus on our GI call point is the fundamental element of our growth strategy. And we are seeing consistent signs of momentum. It's interesting as you characterize the two different paths of sort of converting new writers versus growing existing writers. Virtually all gastroenterologists, not quite all, but a very high percentage of gastroenterologists have already written a script for Bowesna. So we've got broad penetration within the gastroenterology community both among physicians and among APTs with high conversion success already.

    Tristan,非常感謝你的鼓勵和支持,也感謝你把我們引向我認為最重要的話題:我們以胃腸道為核心的呼叫點是我們成長策略的基石。而且我們已經看到了持續的成長動能。你對兩種不同的路徑——開發新用戶和培養現有用戶——的描述很有意思。幾乎所有胃腸病學家(雖然不是全部,但比例非常高)都已經為Bowesna開過處方。因此,我們在胃腸病學界,無論是醫生還是高級執業治療師(APT),都擁有廣泛的市場滲透率,而且轉換率已經很高。

  • What we focus on all of our sales force messaging in the context of our national sales meeting, in the context of the conversations that the regional managers are having with The territory sales representative is all about how to grow writing frequency. We have what we refer to as an adoption ladder where physicians TRY the product and then we are trying to improve their consistency of writing and they become consistent writers and then we TRY to improve their consistency of writing, then they become adopters and so on. And as we grow in terms of the frequency of the physician writing.

    在我們的全國銷售會議上,以及區域經理與區域銷售代表的對話中,我們所有銷售團隊的訊息傳遞都圍繞著如何提高醫生的書寫頻率。我們有一個所謂的“採納階梯”,醫生先試用產品,然後我們努力提高他們書寫的一致性,使他們成為穩定的書寫者,之後我們繼續努力提高他們的書寫一致性,最終他們成為產品的採納者,以此類推。隨著醫生書寫頻率的提高,我們不斷擴大產品的應用範圍。

  • An NRX for Vuesna and what we are seeing is very clear trends on those adoption ladders associated with physicians moving up in categories. So, a tried physician will only have written 2 NRXes in the last quarter. A consistent physician will have written 6 or more weeks in the last quarter, etc. And we are seeing physicians move from one category to the next consistently. Where on one of the metrics we'd only had 40 or 500 physicians last summer that were in the upper categories. Now we've got, well north of 2000 physicians in the upper categories. So, we're seeing that adoption rate among.

    我們觀察到,Vuesna 的 NRX 指標呈現出非常明顯的趨勢,醫生在採用 NRX 的過程中不斷晉升到更高等級。例如,一位經驗不足的醫生在上個季度可能只開立了 2 張 NRX 處方,而一位經驗豐富的醫生在上個季度開立了 6 週或以上的處方,以此類推。我們看到醫生們持續地從一個等級晉升到下一個等級。去年夏天,我們只有 40 到 500 位醫生處於較高等級,現在,處於較高等級的醫生已經超過 2000 位。因此,我們看到醫生們的採用率正在不斷提高。

  • Not just the highest frequency writers, but very broadly within the GI community increasing, and that's the focus of all of our salesforce conversations. That was the focus of our national sales meeting is how do we take physicians through that adoption ladder. It's the focus of each of our coaching conversations and we're seeing clear evidence of it in our writing pattern. One of the metrics that I find to be helpful as we think about the.

    不僅是使用頻率最高的醫生,整個胃腸病學界的使用率都在上升,這也是我們所有銷售團隊討論的重點。我們全國銷售會議的重點是如何引導醫師逐步接受新療法。這也是我們每次輔導對話的重點,我們在寫作模式中也看到了明顯的體現。我認為,當我們思考這個問題時,以下指標很有幫助:

  • Long-term opportunity for this product is, what is the rate of adoption we've achieved among the top few 100 writers, and there we're already seeing that we're now passing on average 20% penetration in terms of their PPI volume being converted to Vuesna. When we get to 20% conversion across the broader GI community, that's where we're approaching a billion dollars of revenue potentially in GI, and that's clearly where we're headed over the next few years.

    這款產品的長期發展機會在於,我們在排名前100位的撰稿人中實現了怎樣的採用率。目前我們已經看到,他們平均有20%的PPI(付費搜尋廣告)轉換為Vuesna。當我們在更廣泛的胃腸病學(GI)領域達到20%的轉換率時,我們在胃腸病學領域的收入潛力將接近10億美元,這顯然是我們未來幾年的發展方向。

  • Operator

    Operator

  • Thank you. Our next question or comment comes from the line of Annabelle Samimi from Stifel. Ms. Samimi, your line is open.

    謝謝。下一個問題或評論來自Stifel公司的Annabelle Samimi女士。 Samimi女士,您的熱線已接通。

  • Annabelle Samimi - Analyst

    Annabelle Samimi - Analyst

  • Hi, thanks for that caller and just following on, from that comment in the territories, that you already have been pretty well aligned as far as the focus on GIs, do you have any sense yet, if, of the dynamic of patients transitioning. Back to primary care, if you're starting to see pull through in some of those more mature, accounts, just curious to see if that dynamic or if you've seen any pickup in the primary care area organically, from that effort, and, when everything, everyone is on board and humming, do you expect an inflection or is this just a steady growth throughout the year? Thanks.

    您好,感謝您的來電。關於您提到的區域性問題,您提到在胃腸道疾病(GI)方面已經取得了相當不錯的進展。您是否已經對病患轉診的動態有所了解?回到基層醫療領域,如果您開始看到一些成熟客戶的病情有所好轉,我很好奇這種動態是否會帶來任何自然增長,或者您是否看到基層醫療領域自發地從這項努力中受益。當一切就緒,所有人都步入正軌時,您預計會出現轉折點,還是會全年保持穩定成長?謝謝。

  • Steven Basta - President and CEO

    Steven Basta - President and CEO

  • So Annabelle, that's a, it's a really important. Component of the long-term growth path is building beyond just GI to capture the return of patients to primary care and the growth there. I just candidly, we've not looked at it, at least I've not looked at it. I know our sales team is doing much more granular work on a physician by physician basis at the specific referral patterns for specific gastroenterologists to see their referring physicians and how they've adopted. I've looked at it much more broadly for the entire universe. Primary care physicians, and we are seeing an uplift in primary care prescribing volume on a broad basis.

    所以安娜貝爾,這確實是一個非常重要的長期成長策略組成部分,那就是要超越胃腸病學領域,抓住患者回歸基層醫療並推動基層醫療成長的機會。坦白說,我們還沒有深入研究過這方面,至少我個人還沒有。我知道我們的銷售團隊正在針對每位醫生,以醫生為單位,進行更細緻的工作,研究特定胃腸病學家轉診醫生的具體模式以及他們如何採納我們的產品。而我則從更廣泛的角度,針對整個基層醫療醫生群體進行了研究,我們發現基層醫療的處方量總體上有所增長。

  • The granularity that you're describing is very much an analysis that over time we will do much more frequently. The near term focus is on that core gastroenterology conversion point. And the expectation exactly to your point is over the next 6, 1,218 months we're going to see those patients returning to primary care and see those growing, and we'll be looking at that metric more precisely.

    您所描述的這種細緻程度的分析,我們將在未來更頻繁地進行。近期重點是核心的胃腸病學轉化點。正如您所說,我們預計在接下來的6個月到12個月內,這些患者將回歸基層醫療機構,而這群人將會成長,我們將更精確地關注這項指標。

  • But what we are seeing on a broad basis when we look at the total prescribing in GI and the total prescribing of primary care is an uplift in both, even though the majority of our sales force time is going into GI, that uplift broadly in primary care prescribing volume would suggest that we are seeing exactly that effect. So, was there a second after your question or did that capture it?

    但從整體來看,當我們觀察胃腸科和初級保健的總處方量時,發現兩者都有所增長。儘管我們銷售團隊的大部分時間都投入了胃腸科,但初級保健處方量的整體增長表明,我們確實看到了這種效應。所以,您的問題之後還有一秒鐘的答案嗎?還是我已經表達清楚了?

  • Annabelle Samimi - Analyst

    Annabelle Samimi - Analyst

  • Expectation for any inflections once everyone is on board.

    一旦所有人都步入正軌,就預計會出現任何變化。

  • Steven Basta - President and CEO

    Steven Basta - President and CEO

  • Oh, the inflection point question. Yeah, so we don't map out, we don't model out a specific inflection point. It's very hard to predict, when does the slope change. What we are driving toward is consistent growth month over month, quarter over quarter, because we're not trying to do a fee change kind of strategy at this point going forward. 2025 was very much a year of fundamentally shifting the strategy. We were changing call points. We realigned sales territories. We went through some pretty significant change. 2026 is just going to be a year of heads down execution.

    哦,拐點的問題。是的,我們不會預先設定或模擬具體的拐點。很難預測斜率何時會改變。我們努力的目標是實現月復一月、季度復一季的持續成長,因為目前我們並不打算採取任何費用調整策略。 2025年是策略進行根本性轉變的一年。我們調整了拜訪點,重新劃分了銷售區域,經歷了一些相當重大的變革。 2026年將是全力以赴執行的一年。

  • It is making sure that we are doing all of the right things. We're getting into the right offices. We're calling on gastroenterologists with the right frequency. We are delivering really good messages every time we call in gastrologists. We're helping them with all of their access needs. We are working through the process of enabling them to write Mwesna scripts more frequently, and that drives our growth. So, we don't need to inflect at any one point to a specifically different strategy. What we need to do is just execute this playbook and execute it well quarter over quarter.

    關鍵在於確保我們所做的每件事都正確。我們拜訪了合適的醫生,以合適的頻率拜訪了腸胃科醫生,每次拜訪都傳遞了清晰有效的訊息。我們幫助他們解決所有就醫方面的需求。我們正在努力讓他們能夠更頻繁地開立Mwesna處方,這推動了我們的成長。因此,我們無需在任何時候調整策略。我們只需要執行這套方案,並且每季都做好。

  • It's hard for me to predict exactly what the slope looks like on a quarter by quarter basis. I do expect that we're going to get steady growth. It might accelerate at some point in time. It's really hard to predict that. What we're seeing is all the right signs of incrementally significant adoption among physicians and incremental success that our sales groups are having in each of these offices.

    我很難準確預測每季的成長趨勢。但我預計我們會保持穩定成長。成長速度可能會在某個時候加快,但這真的很難預測。目前我們看到的是,醫生群體對產品的接受度正在逐步提高,我們的銷售團隊在各個診所也取得了穩定的成功。

  • Operator

    Operator

  • Thank you. Our next question or comment comes from the line of Dennis Ding from Jeffries. Mr. Ding, your line is now open.

    謝謝。下一個問題或評論來自傑富瑞公司的丁丹尼斯先生。丁先生,您的線路已開放。

  • Dennis Ding - Analyst

    Dennis Ding - Analyst

  • Hi, this is Anthea on for Dennis. Thanks for taking our questions and congrats on the quarter. First on Q1, do you expect sequential quarterly growth given the deployment of the expanded sales force? Are you seeing that seasonality plus the winter storms will still be headwinds here? And is there a plan to seek broader Medicare coverage for VewesA this year? And if that's baked into guidance, thank you.

    您好,我是Anthea,代Dennis提問。感謝您回答我們的問題,並祝賀您本季業績出色。首先,關於第一季度,鑑於銷售團隊的擴充,您預期季度將較上季成長嗎?您認為季節性因素和冬季風暴仍會構成不良影響嗎?今年是否有計劃為VewesA爭取更廣泛的Medicare覆蓋範圍?如果這已包含在業績指引中,非常感謝。

  • Steven Basta - President and CEO

    Steven Basta - President and CEO

  • So, Anthea, let me, I'll briefly address the first part and then I'll offer you the opportunity if he wants to add more color on the seasonality in this process. We're clearly seeing the typical seasonality that occurs in the winter storms are clearly having some effect as well. We've seen slow weeks whenever, the entire country is shut down because of an ice storm, that has an impact. The, it's, we don't guide to revenue on a quarter by quarter basis.

    安西婭,讓我先簡單說明第一部分,然後我會給你機會,讓他進一步闡述這個過程中的季節性因素。我們顯然看到,冬季風暴帶來的典型季節性影響也很明顯。每當冰暴導致全國停擺時,我們都會遇到銷售低迷的幾週,這會產生影響。另外,我們不按季發布營收指引。

  • With that granularity, so what we, clearly acknowledge that Q1 is the weakest of the four quarters during the year, whether it's flat or up or down, we just, we don't provide that quarterly guidance. What we've provided is full year guidance. But, the underlying metrics that we're seeing in terms of our sales call activity, the prescribing behavior of physicians, the growth patterns that we've been describing all give us confidence in terms of where we're going to be on a full year basis, and, so Sanjeev, if you want to TRY at all on.

    基於這種細緻的分析,我們明確承認第一季是全年四個季度中最弱的,無論其業績持平、成長或下降,我們都不會提供季度業績指引。我們提供的是全年業績指引。但是,我們從銷售拜訪活動、醫生處方行為以及我們所描述的成長模式等基本指標中看到的,都讓我們對全年業績充滿信心。所以,Sanjeev,如果你想嘗試的話。

  • Sanjeev Narula - Chief Financial and Business Officer

    Sanjeev Narula - Chief Financial and Business Officer

  • Yeah, I think you pointed out, Steve, that we don't, provide quarterly guidance, and but I think what I said this time. If you look at in our kind of prepared remarks that we said earlier, if you look at the cadence of our business on a full year basis, we'll be roughly it kind of same trajectory as we experienced in 2025. 40% of our top-line revenue will be in the first half of the year, approximately 60% in the second half, and I said.

    是的,史蒂夫,我想你已經指出了,我們不提供季度業績指引。但我認為我這次說的是,如果你看看我們之前準備好的發言稿,如果你從全年來看我們的業務節奏,我們會大致延續2025年的發展軌跡。我們40%的總收入將來自上半年,約60%來自下半年。

  • Q1 is going to be the slowest quarter because of typical seasonality. So, I think that's kind of what we see, what the exact number is going to be. Obviously, you'll hear that in the first quarter call that we talk about it, but clearly it is the slowest and softest months with the typical seasonality.

    由於季節性因素,第一季將會是業績最淡的季度。所以,我認為這大致上就是我們最終的業績數字。當然,我們會在第一季財報電話會議上詳細討論這個問題,但很明顯,第一季是業績最淡的月份,受季節性因素影響。

  • Steven Basta - President and CEO

    Steven Basta - President and CEO

  • Right And then the second half of your question, Anthea, I think was related to Medicare. So, we're not anticipating a fundamental change in broad Medicare coverage where we get, coverage for all Medicare patients. What we are seeing. Is incremental Medicare prescriptions being covered either through medical appeals processes or through specific Medicare Part D plans. So as different Medicare Part D plans become more familiar with seeing the Quesna prescriptions being submitted, they are beginning to cover those more frequently. And so we may see over time.

    好的。安西婭,你問題的後半部分,我認為與聯邦醫療保險(Medicare)有關。我們預計聯邦醫療保險的覆蓋範圍不會發生根本性的變化,不會對所有聯邦醫療保險患者都提供保障。我們目前看到的是,透過醫療申訴流程或特定的聯邦醫療保險D部分計劃,越來越多的處方藥開始獲得聯邦醫療保險的報銷。隨著不同的聯邦醫療保險D部分計劃越來越熟悉奎斯納(Quesna)處方的提交情況,他們開始更頻繁地報銷這些處方。隨著時間的推移,我們可能會看到這種情況。

  • Some increase in the number of Medicare scripts that are that are actually being processed and being covered, but it's not a broad coverage decision, nor do we anticipate that there's going to be any broad fundamental change in a in a broad coverage decision on a system-wide basis for the entire population of Medicare patients.

    實際得到處理和報銷的 Medicare 處方數量有所增加,但這並不是一項廣泛的覆蓋範圍決定,我們也不預期會在系統層面上對整個 Medicare 患者群體做出任何廣泛的、根本性的覆蓋範圍決定。

  • Operator

    Operator

  • Thank you. Our next question or comment comes from the line of Joseph Stringer from Needham and Company. Mr. Stringer, your line is open.

    謝謝。下一個問題或評論來自尼德姆公司的約瑟夫·斯特林格先生。史特林格先生,您的電話已接通。

  • Joseph Stringer - Analyst

    Joseph Stringer - Analyst

  • Hi, good morning. Thanks for taking our question. I just wanted to follow-up on the previous question, looking at the IQVA prescription data and the impact of seasonality is the magnitude of the seasonality affect this cycle in line with your expectations, I guess, all things considered, and maybe another way of asking is it, are there any nuances about the launch now with the refocused effort that would make it more or less sensitive to seasonality? Thank you.

    您好,早安。感謝您回答我們的問題。我想就之前的問題做個後續說明:根據IQVA的處方資料以及季節性因素的影響,我想問一下,本週期季節性因素的影響程度是否符合您的預期?考慮到所有因素,或許可以換個方式問:鑑於目前重新調整了工作重點,產品上市過程中是否存在一些細微差別,使其對季節性因素的敏感度更高或更低?謝謝。

  • Steven Basta - President and CEO

    Steven Basta - President and CEO

  • So, thank you for the question. It's really hard to characterize magnitude of seasonality one year versus another. What we're seeing is very similar to the pattern that we saw last year in terms of January being particularly light and then February is also light, and then by March last year, it started to pick up. So, we would hope that that same pattern, and not just hope, we actually expect that that same pattern is going to come to fruition. Because you get several uplifts in March. We're coming off of the national sales meeting. Everybody's energized. We're going to have a full-strength sales organization, and physicians have had time to work through their plans. Patients who have switched plans now have time to figure out how they're going to get the drug covered.

    謝謝你的提問。要準確描述每年季節性波動的幅度確實很難。我們目前觀察到的情況與去年非常相似,一月銷量特別低,二月銷量也很低,然後到了三月開始回升。所以,我們希望——不只是希望,我們實際上預期——今年的模式會與去年相同。因為三月通常會有幾次銷售成長。我們剛結束了全國銷售會議,大家都精神抖擻。我們將組成一支強大的銷售團隊,醫生們也有時間完善他們的計畫。更換健保計畫的患者現在也有時間考慮如何獲得藥品報銷。

  • So all of those things that create noise in January as everybody's switching to a new health plan gets worked out in the 1st month or two. So that effect just is there every year for a branded product, and we, the specific magnitude of it varies by product, so we're starting to see what that pattern looks like for us, not seeing anything that's unusual in that regard.

    所以,一月大家紛紛更換健保計畫時產生的各種幹擾因素,都會在前兩個月逐漸消失。這種影響每年都會出現在品牌產品中,只是具體程度因產品而異。我們開始觀察這種模式在我們這裡是如何體現的,目前為止還沒有發現任何異常情況。

  • One thing that we have observed is the IQBA reported numbers seem to be somewhat greater underreporting versus our internal numbers than historic norms. We think we've identified the causes. That that that's going to work itself out, but there may be a little bit of extra softness or delta in the IQ of your reported numbers versus what we're actually seeing, but the softness is real in January and February, and we think it starts to improve meaningfully in March.

    我們觀察到的一點是,IQBA報告的數據似乎比我們內部的數據低一些,低於歷史平均值。我們認為已經找到原因了。這種情況會逐漸好轉,但你們報告的數據與我們實際觀察到的數據之間可能存在一些偏差,尤其是在1月和2月,我們認為3月份情況會開始顯著改善。

  • The other phenomenon that you cite is a real phenomenon, as as Anthea's question also. It suggested that, the winter storms clearly not just had an effect on us, had an effect on a whole bunch of companies in the context of the slowdown for a week in January and slowdown for a week in February on the Northeast. So, I don't want to overstate those, that is, the dominant effect is just the annual seasonality that we would expect to see every year.

    你提到的另一個現象確實存在,就像安西亞提出的問題一樣。這表明,冬季風暴的影響顯然不僅限於我們,而是波及到東北地區一月份和二月份各一周的業務放緩,影響範圍相當廣泛。所以,我不想誇大這些影響,也就是說,主要影響還是我們每年都會遇到的季節性因素。

  • Operator

    Operator

  • Thank you. Our next question or comment comes from the line of Paul Choi from Goldman Sachs. Mr. Choi, your line is now open.

    謝謝。下一個問題或評論來自高盛的Paul Choi先生。 Choi先生,您的線路已開放。

  • Paul Choi - Analyst

    Paul Choi - Analyst

  • Morning team. This is Daniel on for Paul. Thanks for creating a question. So, we're curious about like if you could provide colors on the proportions of prescriptions that are now filled to Blink Rx versus the new, GoodRx that came online and how is the economy of the channels versus the more traditional, dis dispensary. Thank you.

    早上好,各位。我是丹尼爾,替保羅回答問題。感謝您提出問題。我們想了解的是,您能否提供一下目前透過 Blink Rx 和新上線的 GoodRx 平台配藥的比例,以及這些管道的經濟效益與傳統藥房相比如何?謝謝。

  • .

    。

  • Steven Basta - President and CEO

    Steven Basta - President and CEO

  • So, there's several different parts to that. So let me take GoodRx first. GoodRx, we just turned on in November, and what that is, I mean, already GoodRx had coupons on it for our co-pay support program. So if someone is at a pharmacy with a retail script and they need to get copay support because their insurance copay is high, they can go to GoodRx, they can get our copay card and, in many cases, bring down the copay amount significantly and in some cases down to $25 which is our target co-pay where possible. The other thing that we turned on with GoodRx is the opportunity to do a cash pay purchase through GoodRx, which actually still would get reported into the IQVA script numbers because there would be. Dispensed from a retail pharmacy, but there's a $199 option for a patient to purchase that.

    所以,這其中包含幾個不同的部分。首先,我來說說GoodRx。 GoodRx是我們去年11月剛上線的,它其實已經提供了我們自付額支持項目的優惠券。所以,如果有人拿著零售處方去藥局取藥,但因為保險自付額很高,需要獲得自付額支持,他們可以透過GoodRx申請我們的自付額卡。在許多情況下,這張卡可以大幅降低自付額,有些情況下甚至可以降到25美元,這是我們盡可能設定的目標自付額。 GoodRx的另一個功能是允許用戶透過GoodRx進行現金支付,雖然這筆交易仍然會被計入IQVA的處方數量,因為藥品仍然是從零售藥房配發的,但患者可以選擇以199美元的價格購買。

  • That's intended really for a patient who either can't access the copay card because they're on a government plan or for whom the copay would still be too high, or would still be above $199 that it gives another alternative per patient. Those numbers are still relatively small. It's a very small percentage of the overall number. It just got turned on.

    這項政策主要針對那些因為參加政府健保計畫而無法使用共付卡,或者共付額仍然過高(超過 199 美元)的患者,為他們提供另一種選擇。目前這些患者人數仍然相對較少,僅佔總人數的一小部分。這項政策剛剛啟用。

  • In November we'll give you a sense in future quarters if that grows to be a meaningful number, we'll give some color on that, but at this point it's it's a really small number. It's not a driver of anything, but don't want anybody to be surprised that that option now exists. So, we're trying to provide multiple ways for a patient in different reimbursement circumstances and different access environments to be able to know that they're going to be able to get access to the product as reasonably priced as possible.

    11月我們會公佈一些數據,讓大家了解未來幾季這個數字是否會成長到有意義的程度,屆時我們會詳細說明。但目前這個數字還很小,不會對任何事情產生影響,但我們不想讓大家對現在有這個選擇感到驚訝。所以,我們正在努力為不同報銷情況和不同就醫環境的患者提供多種途徑,讓他們能夠以盡可能合理的價格獲得產品。

  • The percentage of scripts that are going through blink. And I want to be Sort of clear to distinguish between two things in this process. More than half of our prescriptions now in total are going. Through the blink network to then be routed either as covered scripts to a pharmacy or as cash pay scripts to be dispensed directly through the blink network. If when a physician sends a prescription to designates a prescription to go to blank, blink will first adjudicate whether or not the script is going to get covered.

    處方透過 Blink 系統處理的比例是多少?我想在過程中明確區分兩件事。目前,我們超過一半的處方都透過 Blink 網路處理,然後根據情況分為兩種:一種是醫保覆蓋的處方,另一種是自費處方,由 Blink 網路直接配藥。如果醫生將處方指定寄至 Blink,Blink 將首先判定該處方是否符合醫保覆蓋範圍。

  • If it gets covered, it shows up in the IQ via numbers. It doesn't show up in our blink cache numbers even though blink is an intermediary facilitated that process. So, about half of our scripts in total go to blink. They get routed. If they get covered, they show up in the IQVA numbers. If they don't, they show up in our cache numbers, and as we described, something on the order of 36% of our prescriptions now are blink dispensed cash scripts. So that's where the two different numbers are, that delta is scripts that are getting covered after they originally got sent to blank. Matthew, does that address your question, or is there a second part of that?

    如果處方被報銷,就會在IQ系統中顯示出來。即使Blink作為中間機構促成了這個過程,它也不會出現在我們的Blink快取編號中。所以,我們大約一半的處方會先經過Blink,然後再被路由。如果處方被報銷,就會出現在IQVA編號中。如果處方沒有被報銷,就會出現在我們的快取編號中。正如我們之前提到的,現在大約有36%的處方是透過Blink配發的現金處方。這就是兩個不同數字的由來,差值代表的是那些最初被送到空白系統後又被報銷的處方。 Matthew,這能解答你的疑問嗎?還是還有後續問題?

  • Operator

    Operator

  • That's fine. Thank you very much.

    好的,非常感謝。

  • Steven Basta - President and CEO

    Steven Basta - President and CEO

  • Yes, sir.

    是的,先生。

  • Operator

    Operator

  • Thank you. Our next question or comment comes from the line of Chase Knickerbocker from Craig Hallam. Sir, your line is open.

    謝謝。下一個問題或評論來自克雷格·哈勒姆的蔡斯·尼克博克先生的留言線。先生,您的留言線已接通。

  • Chase Knickerbocker - Senior Research Analyst

    Chase Knickerbocker - Senior Research Analyst

  • Good morning. Thanks for taking the question. Just a quick one, Steve, what inning do you think we are in as far as kind of getting reps to pull the productivity or kind of where you expect them to be after kind of shifting the focus in the fall, but also kind of changing the lines of like some of the geographical lines of a lot of these territories in the fall as well. Where do you think we are as far as the in there?

    早安.感謝您回答這個問題。史蒂夫,我只想問一個簡單的問題:就目前的情況來看,我們進行訓練以提升效率,或者說,在秋季調整了訓練重點以及一些地區的地理劃分之後,我們目前的進度如何?您認為我們現在處於什麼階段?

  • Steven Basta - President and CEO

    Steven Basta - President and CEO

  • Just to clarify, Chase, what inning of Salesforce transition.

    Chase,請確認一下,Salesforce 過渡進行到哪一階段了?

  • Chase Knickerbocker - Senior Research Analyst

    Chase Knickerbocker - Senior Research Analyst

  • Just to start getting into the full productivity Step As far as full productivity, kind of with that transition in the fall, yeah.

    要真正進入全面提高生產力的階段,就得等到秋季的過渡期了,是的。

  • Steven Basta - President and CEO

    Steven Basta - President and CEO

  • So I think, full productivity for a sales rep comes several months after the sales rep is on board because there's a training process, there's a learning process. It takes a month or two to get to know the accounts in your territory and to schedule all of the launch events. So, we had a number of sales training classes that came. In January and then our national sales meeting in February.

    所以我認為,銷售代表要到入職幾個月後才能完全發揮業績,因為需要一個培訓和學習的過程。他們需要一到兩個月的時間來熟悉自己負責區域的客戶,並安排好所有的產品發布活動。因此,我們在1月舉辦了一系列銷售培訓課程,然後在2月舉行了全國銷售會議。

  • By March, April, all of those folks are hitting the ground. I mean, they're hitting the ground immediately after their training program, but within a month or two they've met most of the accounts in their territory and they've got their lunches scheduled and they've got momentum within each of those accounts and you start to see the real impact. So, I would think we are. To use the baseball analogy at the 7th or 8th inning of that 9 inning process, of sort of the sequence of events where the sales force gets to be fully effective.

    到了三、四月份,這些人就都開始步入正軌了。我的意思是,他們在培訓結束後就立刻投入工作,一兩個月內,他們就拜訪了轄區內的大部分客戶,安排好了午餐時間,在每個客戶那裡都建立了良好的業績勢頭,你開始看到真正的成效。所以,我認為我們現在的情況是,用棒球比賽來打比方,銷售團隊在九局比賽的第七局或第八局,也就是銷售團隊全面發揮作用的階段。

  • Chase Knickerbocker - Senior Research Analyst

    Chase Knickerbocker - Senior Research Analyst

  • And sort of since that, shift of focus in GI, have you seen kind of the increase in productivity that having, more kind of condensed patient base at these prescribers, would indicate, or do you think there's kind of additional efficiency that we'll continue to kind of harvest over the course of this year?

    自從胃腸道疾病的關注點發生轉變以來,您是否看到,由於這些處方醫生的患者群體更加集中,生產力有所提高?或者您認為,今年我們還能繼續提高效率嗎?

  • Steven Basta - President and CEO

    Steven Basta - President and CEO

  • Well, it's interesting. Even if the sales force is fully effective, you don't see the effect. That day or that week or even that month in terms of sales, because the majority of our prescriptions come from Prior patients who have been prescribed the product who are getting refills, physicians who have previously already adopted the product who are prescribing it to a, an incremental physician. So, what we are really doing is just moving.

    嗯,這很有意思。即使銷售團隊效率極高,你也看不到實際效果。無論是當天、當週還是當月,銷售額都不會有明顯變化,因為我們的大部分處方都來自之前使用過該產品的患者續方,以及之前已經採用該產品的醫生將其推薦給其他醫生。所以,我們其實只是在推廣而已。

  • The incremental adoption rate. So, if you've sort of got a base 70% to 80% volume that's happening, you're really only impacting that 20%. Now if you become 30% more effective, that 20% goes to 26%, but it's 26% on top of a base 80% that already exists there. So, when you see it, you don't see, when you see a greater effectiveness in our sales activities, you don't see an immediate change in revenue in a month.

    增量採用率。所以,如果現有銷售量佔比在 70% 到 80% 之間,那麼你其實只能影響剩下的 20%。現在,如果你的效率提高了 30%,那麼這 20% 的份額就會增加到 26%,但這 26% 是在原有 80% 的基礎上增加的。因此,即使銷售活動的效率提高了,你也不會在一個月內立即看到收入的變化。

  • What you see is incremental effectiveness, but that incremental effectiveness is cumulative over time. Because the increased conversions of patients in that month aren't just scripts that month, they are refilled the next month and are refilled the next month and are refilled the next month, and the incremental scripts the next month refilled every month thereafter, so you see a cumulative growing effect. You don't have a sale sources activity turned into a fee change in revenue in that next month of revenue. If that makes sense, it's sort of how these how these consistent use products end up building over time.

    你看到的是漸進式的效果,但這種漸進式的效果是隨著時間的推移而累積的。因為當月病患轉換率的提高不僅體現在當月的處方上,還包括下個月的續方、再下個月的續方、再下個月的續方,以及之後每個月的續方,所以你會看到一種累積成長的效果。你看到的不是銷售來源活動直接轉化為下個月收入的變化。如果這樣解釋你能理解的話,這就是這些持續使用型產品最終如何隨著時間推移而累積效益的原理。

  • Chase Knickerbocker - Senior Research Analyst

    Chase Knickerbocker - Senior Research Analyst

  • Thank you for.

    謝謝。

  • Operator

    Operator

  • Thank you. Our next question or comment comes from the line of Min Lee from Guggenheim Partners. Mr. Lee, your line is now open.

    謝謝。下一個問題或評論來自古根漢合夥公司的李敏先生。李先生,您的線路已開放。

  • Min Lee, Ph.D. - Analyst

    Min Lee, Ph.D. - Analyst

  • Hi guys, thank you for the questions and correction data. One quick question for me, what is the company's, long-term vision beyond Vuesna? I mean, given that you guys have established this GI network, do you guys plan to utilize this network to consider, maybe future partnership with companies that have already commercially ready GI assets, or do you guys plan to maybe, pursue any other indications beyond EOE? Thank you.

    大家好,感謝你們提出的問題和提供的更正數據。我還有一個問題,貴公司除了Vuesna之外的長期發展願景是什麼?我的意思是,鑑於你們已經建立了這個GI(胃腸道)網絡,你們是否計劃利用這個網絡,考慮未來與那些已經擁有商業化GI資產的公司建立合作關係?或者你們是否計劃開發除EOE(嗜酸性粒細胞性貧血)以外的其他適應症?謝謝。

  • Steven Basta - President and CEO

    Steven Basta - President and CEO

  • So, Min, thank you for the question. So, at this point, the only new indication that we're pursuing actively is EOE for V Quesna. There are other indications and other populations that are of interest that we're evaluating. We've made no decisions. For example, we did a phase 2 trial for as needed use. Haven't made a decision yet about whether or not we wish to pursue that in a phase 3 program, but there are, other populations that also could be of interest.

    敏,謝謝你的提問。目前,我們正在積極推進的唯一新適應症是V Quesna的嗜酸性粒細胞性食道炎(EOE)。我們也正在評估其他適應症和其他族群,但尚未做出任何決定。例如,我們進行了按需用藥的第二期臨床試驗,尚未決定是否進行第三期臨床試驗,但還有其他族群也可能值得關注。

  • Our long-term growth plan, as we have indicated, is to build a GI company that will bring in additional assets. This year is very much a year of consolidating our execution plan, building deep relationships at every gastroenterology office. 300 person field force is going to have those deep relationships and is going to be fostering them and build a leverageable base that we could bring a second product into.

    正如我們之前所述,我們的長期成長計畫是打造一家能夠帶來更多資產的胃腸道公司。今年,我們的重點是鞏固執行計劃,與每家胃腸病診所建立深厚的合作關係。我們將組建一支300人的銷售團隊,負責維護和拓展這些關係,並以此為基礎,推出第二款產品。

  • We are also starting, BD activities to explore what other products would make sense, either to bring in a commercial product potentially or very possibly a phase 2 or phase. 3 clinical stage product that could launch in a 2030, 2031, 2032, time frame before we get to our LOE date so that we're launching not just probably a product but two or three products over the course of the next 4 or 5 years that would build out a GI pipeline. So, we're starting those conversations. We have had people. Bring us several ideas that are interesting. I don't feel any urgency that we need to distract our sales force to the second product right now. We just need to grow a Quesna.

    我們目前也正在進行業務拓展活動,探索其他可能適合的產品,包括潛在的商業化產品,或者很可能是處於二期或三期臨床試驗階段的產品,這些產品預計在2030年、2031年或2032年上市,也就是在我們達到預期療效期限(LOE)之前。這樣,我們未來四、五年內不僅可能推出一款產品,而是兩到三款產品,從而建造起一套完整的胃腸道產品線。所以,我們正在著手進行這些討論。有些人已經向我們提出了一些很有趣的想法。我認為目前沒有必要讓我們的銷售團隊分心去開發第二款產品。我們現在需要做的就是發展壯大Quesna公司。

  • We need to just execute on our core activity set, but we are actively thinking about what products would make sense to bring in and to launch over the next 2 to 5 year period of time. And that could mean products at various stages from commercial down to phase 2 stage, but it has to be launchable within the next 2 to 5 years, so that it's launched before LOE date in 2033 or 2034.

    我們目前只需專注於核心業務,但同時也積極思考未來2到5年內應該引進和推出哪些產品。這可能包括處於不同階段的產品,從商業化階段到第二期臨床試驗階段都有可能,但必須確保在未來2到5年內能夠上市,以便在2033年或2034年產品生命週期結束前推出。

  • Operator

    Operator

  • Thank you. Our next question or comment comes from the line of Martin Auster from Raymond James. Mr. Auster, your line is now open.

    謝謝。下一個問題或評論來自Raymond James公司的Martin Auster先生。 Auster先生,您的電話線路已接通。

  • Martin Auster - Equity Analyst

    Martin Auster - Equity Analyst

  • Thanks. Congratulations on the successful 2025 and in particular the recent steps you guys have taken to strengthen the balance sheet. I'm going to maybe follow-up on one of the earlier questions on, I appreciate your comments you guys made on Q1 seasonality. I guess I was curious if the plan resets and other factors that kind of contribute to seasonality, does that drive an uptick in the rate of cash pay patients you'd expect to see in the quarter? And then also on the gross to net guidance system you provided, curious if there's any trends that are assumed within that 55% to 59% range or if that metric is expected to be pretty steady overall throughout the year. Thanks.

    謝謝。恭喜你們在2025年取得成功,尤其恭喜你們最近為加強資產負債表所採取的措施。我想就之前的一個問題再問幾句,感謝你們對第一季季節性因素的評論。我想問的是,如果計劃重置以及其他一些影響季節性的因素,是否會導致你們預期在第一季看到的自費患者比例上升?另外,關於你們提供的毛利淨利指引,我想知道在55%到59%的範圍內是否存在任何趨勢假設,或者這個指標預計全年都會保持相對穩定?謝謝。

  • Steven Basta - President and CEO

    Steven Basta - President and CEO

  • So, thanks, Martin. Appreciate the kind thoughts on the questions. I'll take the first half, which is around cash pay, and the second half I'll give to Sanjeev in terms of GTN and sort of expectations. We would expect that we'll see some uptick in the amount of cash pay patients. I don't have any guidance on, how much that is. I don't think it's going to be, too.

    謝謝馬丁。感謝你對這些問題提出的寶貴意見。前半部分,也就是關於自費的部分,我先回答;後半部分,關於GTN(全球治療網絡)以及預期情況,我會交給桑吉夫回答。我們預計自費患者的數量將會增加。至於具體增加多少,我目前還無法給出具體數字。我覺得應該不會太多。

  • Significant in that process, but you'll see some patients who have a high deductible plan where they will be able to get access to the product on a cash basis from blink, and then as they work through their deductibles, they would then be able to get it covered at some, later period. And so, you may see some movement in cash pay percentage in the early months of each year. That's not just this year, that would just be in general as a pattern. In this process, we don't provide guidance on what that mix is going to be on a quarter to quarter basis, but that would be a typical feature of the seasonality patterns that one might expect. Separately in terms of GTN and patterns and trends on GTN, Sanjeev, do you want to take that?

    在這個過程中,現金支付比例可能會出現波動,但有些患者購買的是高免賠額保險計劃,他們可以透過 Blink 以現金購買產品。隨著免賠額的逐步支付,他們之後就可以享受保險報銷。因此,您可能會看到每年年初現金支付比例出現一些波動。這並非今年特有的現象,而是一種普遍的模式。我們不會提供每季具體的現金支付比例預測,但這確實是季節性波動的典型特徵。另外,關於 GTN 的模式和趨勢,Sanjeev,您想談談嗎?

  • Sanjeev Narula - Chief Financial and Business Officer

    Sanjeev Narula - Chief Financial and Business Officer

  • Yeah, I'll take that seat. Thank you. So, Martin, as you saw like in 2025, so we kind of narrowed the guidance if you recall. It got Q3 called to 55%-60% and right through the last year we were kind of operating within that range, quarter to quarter there are variations because, your plan business may change from one quarter to the other, but overall it was very consistent and stable, and that's kind of what I expect in the guidance that, we gave early this morning. 55% to 59% overall for the full year we will be within that guidance quarter to quarter there could be changes depending upon how the plan flows and the business flows from that perspective.

    好的,我坐那兒。謝謝。馬丁,正如你所看到的,在2025年,我們縮小了預期範圍,如果你還記得的話。第三季預期是55%-60%,去年我們一直都在這個範圍內運作。每個季度都會有一些波動,因為業務計劃可能會因季度而異,但總體而言非常穩定。這也是我今天早上給的期待。全年預期是55%-59%,我們會在這個預期範圍內,每季可能會根據計畫和業務的進度有所調整。

  • Operator

    Operator

  • Thank you. Thank you. Again, ladies and gentlemen, if you have a question or comment at this time, please press 11 on your telephone keypad. Our next question or comment comes from the line of Matthew Caufield from HC Wainwright. Mr. Caufield, your line is now open.

    謝謝。謝謝。女士們、先生們,如果您現在有任何問題或意見,請按電話鍵盤上的11。下一個問題或意見來自HC Wainwright公司的Matthew Caufield先生。 Caufield先生,您的線路已接通。

  • Matthew Caufield - Equity Analyst

    Matthew Caufield - Equity Analyst

  • Great, hi, thank you guys. We had one question on the landscape that came up from investors. There's a separate private company with later stage clinical development in non-erosive reflux disease and erosive esophagitis based on the PCA formulation and just curious on your longer-term thoughts on any prospective entrance into the PCA space, later into the future and, maintaining Vuesma's positioning. Thanks again.

    太好了,謝謝各位。我們有一個來自投資者的關於市場格局的問題。有一家獨立的私人公司正在基於PCA配方進行非糜爛性​​逆流和糜爛性食道炎的後期臨床開發,我們想了解你們對未來是否可能進入PCA領域,以及如何保持Vuesma現有市場地位的看法。再次感謝。

  • Steven Basta - President and CEO

    Steven Basta - President and CEO

  • Hi Matthew, thanks so much for the question. I apologize. I muted for a second, to cough. I just have a little bit of a cold, but I think you're likely referring to Sabella, which is a company that has to go in development. There's actually an additional PA that's in development that's many years out, so we, clearly track competitive developments, all of the PABs, and Tooprazan is a good product. We expect that it will, go through the NDA process, and they filed their NDA. In January, reasonable to expect they may be approved by early 2027, but it's not really for us to predict exactly what that time frame is or what questions might arise.

    嗨,Matthew,非常感謝你的提問。抱歉,我剛才靜音了一會兒,咳嗽了一下。我有點感冒,但我想你可能指的是Sabella,這是一家需要研發的公司。實際上,還有另一種PA(上市前藥物)也在研發中,但還需要很多年才能上市。所以我們一直在密切關注競爭對手的進展,包括所有PAB(上市前藥物),而Tooprazan是一款不錯的產品。我們預計它將完成NDA(新藥申請)流程,他們也已經提交了NDA申請。預計他們可能會在2027年初獲得批准,但我們無法準確預測具體的時間範圍或可能出現的問題。

  • One of the things that we think about is how did this market evolve as a second entrant in the PCA space comes in. And it's interesting, there's one framework where sort of a question can arise, are two PAs going to compete against each other? There's a different question, which is we're competing in a space of 110 million PPI prescriptions per year. And we've only done 1.1 million prescriptions overall since launch, so we're tracking now at a run rate that's running about a million prescriptions a year. So, we're at 1% of the PPI market. If a second entrant comes in, they're not going to be trying to.

    我們思考的問題之一是,隨著第二個PCA(個人護理助理)進入市場,這個市場將如何演變。有趣的是,從某個角度來看,可能會出現這樣的問題:兩個PA(個人護理助理)之間會競爭嗎?另一個問題是,我們身處一個每年有1.1億張PPI(質子幫浦抑制劑)處方的市場。而自公司成立以來,我們總共只開了110萬張處方,也就是說,我們目前的年開量約為100萬張。因此,我們只佔PPI市場的1%。如果第二個進入者出現,他們肯定不會試圖與我們競爭。

  • Take prescriptions. We're both going to be growing the PA awareness in the context of the market where patients are on PPIs and are significantly in pain on PPIs. The entry of a second product in a new category actually does have a tendency to change the mindset of physicians where It's no longer do I need to pay attention to this product if you're the first entrant, but it's, do I need to pay attention to this category, and that increase in category awareness, I actually think will accrue to our benefit that the majority of prescriptions tend to go.

    就拿處方來說吧。我們雙方都將致力於提高人們對質子幫浦抑制劑(PPI)的認知度,尤其是在患者服用PPI後疼痛劇烈的情況下。第二個產品進入新類別確實會改變醫生的思維模式,他們不再會問“如果你是第一個進入者,我是否需要關注你的產品”,而是會問“我是否需要關注這個類別”。我認為,這種類別認知度的提高實際上對我們有利,因為大多數處方最終都會流向PPI。

  • To the first entrant that has more history with which physicians are more comfortable that already has broad access, so the second entry tends to grow the big, the category broadly and tends to grow revenue for both parties in that process. So we're actually Thinking that it has a net, positive effect on the PA adoption broadly to have a second sales force out talking about PCABs and how much value they can bring to a patient who is still in pain on a PPI.

    對於第一個進入市場的品牌來說,由於其擁有更悠久的歷史、醫生更熟悉且市場覆蓋面更廣,因此第二個進入市場的品牌往往會推動整個品類的大規模增長,並在此過程中為雙方帶來收益。所以我們認為,第二個銷售團隊積極推廣PCAB(前列腺素受體拮抗劑)及其對仍在服用PPI(質子幫浦抑制劑)的疼痛患者的價值,實際上會對PA(前列腺素受體拮抗劑)的普及產生正面影響。

  • So we're looking forward to that broadening and that shift in mindset of physicians that you really do need to adopt PPIs. We think we've got a great product. We think that physicians have been, we know physicians have been really pleased with the effect that this has for their patients, and patients who take this product love it. All of that is going to reinforce the fact that the lead product in the category gets the biggest uptick.

    因此,我們期待醫生們的觀念能夠拓展和轉變,真正認識到PPI(質子幫浦抑制劑)的必要性。我們認為我們的產品非常出色。我們知道,醫生們對這款產品帶給患者的療效非常滿意,服用這款產品的患者也對它讚不絕口。所有這些都將進一步鞏固這樣一個事實:該品類中的領先產品能夠獲得最大的成長。

  • Matthew Caufield - Equity Analyst

    Matthew Caufield - Equity Analyst

  • Understood. That was really helpful. I appreciate it and congrats again on Vuesna's trajectory. It's great to see.

    明白了。這真的很有幫助。非常感謝,再次恭喜維斯納所取得的成就。看到他取得這樣的成績真是太好了。

  • Operator

    Operator

  • Thank you. I'm showing no additional questions in the queue at this time. Ladies and gentlemen, thank you for participating in today's conference. This concludes the program. You may now disconnect, everyone, have a wonderful day. Speaker, standby.

    謝謝。目前隊列中沒有其他問題。女士們、先生們,感謝各位參加今天的會議。本次會議到此結束。大家可以斷開連線了,祝大家有個美好的一天。演講者,請稍候。